WuXi AppTec, a Chinese pharmaceutical services provider, reported record fourth-quarter revenue of CNY11.5 billion, marking a 7% year-on-year increase, and a net profit of CNY2.917 billion, up 27.21% quarter-on-quarter. The company also highlighted a 91% year-on-year surge in Q4 profit and forecasted double-digit revenue growth of 10%-15% for 2025, projecting total revenue to reach between CNY41.5 billion and CNY43 billion. The firm’s shares surged following the announcement, with its Hong Kong-listed stock rising 9.7% and Shanghai-listed shares climbing 8.8%. WuXi AppTec announced a share buyback program and noted that its 2024 revenue totaled CNY39.2 billion, with a net profit of CNY9.4 billion. The company attributed part of its performance to discontinued operations, including the sale of WuXi Advanced Therapies and other units to Altaris. WuXi AppTec stated that its U.S. revenue, which grew 7.7% last year to CNY25 billion, remains unaffected by the proposed Biosecure Act aimed at restricting Chinese biotech firms' access to U.S. government contracts and sensitive data. The company continues to monitor legislative developments and engage with policymakers on the matter.